Sanofi offloads more consumer health brands to STADA in Europe

12 Jul 2023
firstwordpharma.com
AcquisitionBiosimilar
STADA Arzneimittel announced Wednesday that it is acquiring another range of consumer healthcare brands from Sanofi across European countries, including in Belgium, Germany, Hungary, Spain and the UK, as well as Nordic countries. The transaction, whose financial terms were not disclosed, is scheduled to close in the fourth quarter.
In 2021, STADA acquired 16 of Sanofi's consumer healthcare products across 13 countries in Europe and shortly afterwards entered into a deal to distribute and market Sanofi's portfolio of consumer healthcare brands in 20 European countries. It has since agreed to distribute Sanofi's consumer healthcare portfolio in 10 countries in Central Asia as well.
"We are pleased to continue our collaboration with Sanofi," stated CEO Peter Goldschmidt, adding that the latest acquisition "further strengthens STADA as a top-four player in Europe's consumer healthcare market and supports our growth acceleration." Goldschmidt said "the brands being acquired, and their geographic presence, are well aligned and synergistic with the organic activities in [our] core countries."
The new transaction covers Antistax for pain relief and tiredness in the legs; the allergy eye drops Lomudal and Opticrom; Omnivit vitamins; pain drugs AAS and Dolalgial; as well as Bila-Git for gallbladder complaints.
In 2019, STADA acquired Takeda's portfolio of 20 prescription and over-the-counter drugs for $660 million, later tapping GSK for 15 consumer healthcare brands.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.